Medicinal cannabis oil containing both cannabidiol (CBD) and a small amount of THC can reduce or end seizures in children with severe, drug-resistant epilepsy, a study by the University of Saskatchewan (USask), Canada has found. Children with severe drug-resistant epilepsy also experienced improvements in their quality of life after takingRead
The disabling condition of obsessive-compulsive disorder (OCD) affects about 2–3% of people worldwide. Evidence suggests that abnormalities in cortico-striatal-thalamic-cortical circuitry and specific gene variants contribute to the pathogenesis of the disorder. This latest study, published in Cannabis and Cannabinoid Research, suggests that the endocannabinoid system (ECS) plays a role in OCD symptomsRead
New Rochelle, NY, May 7, 2019—Cannabis and Cannabinoid Research (CCR) is extremely excited to announce that the International Cannabinoid Research Society (ICRS) has named CCR its Official Journal. The ICRS is a foremost international society spearheading scientific research in all fields of cannabinoids, ranging from biochemical, chemical, and physiological studiesRead
Patients are aware that medical cannabis and cannabinoid derivatives are available to treat pain and symptoms. However, the medical literature to guide palliative medicine physicians in recommending cannabis and cannabinoid use is not yet well developed. The Journal of Palliative Care, David Casarett, MD, Guest Editor and Chief of Palliative CareRead
Neurotransmitters and neurochemicals can act on lymphocytes by binding to receptors expressed by lymphocytes. This review describes lymphocyte expression of receptors for a selection of neurotransmitters and neurochemicals, the anatomical locations where lymphocytes can interact with neurotransmitters, and the effects of the neurotransmitters on lymphocyte function. Implications for health andRead
As more states legalize medical cannabis, clinicians are seeking more information on how it may affect elderly populations for chronic conditions associated with aging. In this study, published in the journal Neurology, researchers evaluated medical cannabis’ (MC) efficacy and adverse effects (AE) in patients 75 years of age or older.Read
Statement from FDA Commissioner Scott Gottlieb, M.D., on new steps to advance agency’s continued evaluation of potential regulatory pathways for cannabis-containing and cannabis-derived products In recent years, we’ve seen a growing interest in the development of therapies and other FDA-regulated consumer products derived from cannabis (Cannabis sativa L.) and itsRead
Physical inactivity is a common factor in lifestyle diseases – and one that is often linked to the excessive consumption of fatty and/or sugary foods. The opposite scenario of excessive physical activity at the expense of caloric intake can also be harmful, as cases of anorexia nervosa illustrate. These scenariosRead
“The brain and the gut speak the same language” (1) Ethan Russo, MD, Renown Cannabinoid Scientist The endocannabinoid system (ECS) is a network of receptors and enzymes that are spread throughout the body. This system can interact with one’s own cannabinoids (endogenous or endocannabinoids) because of substances found in natureRead
Weekly round-up, access to thought leaders, and articles to help you improve health outcomes and the success of your practice.
